Real-World Evidence of the Cambridge Hybrid Closed-Loop App With a Novel Real-Time Continuous Glucose Monitoring System

Christine Newman; Sara Hartnell; Malgorzata Wilinska; Heba Alwan; Roman Hovorka

doi:10.1177/19322968231187915

Real-World Evidence of the Cambridge Hybrid Closed-Loop App With a Novel Real-Time Continuous Glucose Monitoring System

J Diabetes Sci Technol. 2023 Jul 28:19322968231187915. doi: 10.1177/19322968231187915. Online ahead of print.

Authors

Christine Newman¹, Sara Hartnell¹, Malgorzata Wilinska^{2

3}, Heba Alwan^{2

4}, Roman Hovorka^{2

3}

Affiliations

¹ Wolfson Diabetes and Endocrinology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
² Wellcome-MRC Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge, Cambridge, UK.
³ Department of Paediatrics, University of Cambridge, Cambridge, UK.
⁴ Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.

PMID: 37503893
DOI: 10.1177/19322968231187915

Abstract

We evaluated the performance of the interoperable Cambridge hybrid closed-loop app with FreeStyle Libre 3 glucose sensor, and YpsoPump insulin pump in a real-world setting. Data from 100 users (63 adults [mean ± SD age 41.9 ± 14.0 years], 15 children [8.6 ± 5.2 years)] and 22 users of unreported age) for a period of 28 days were analyzed. Time in range (3.91- 10.0mmol/L) was 72.6 ± 11.1% overall. Time below range (<3.9mmol/L) was 3.1% (1.4-5.1) (median [interquartile range]). Auto-mode was active for 95.8% (91.8-97.9) of time. This real-world analysis suggests that the performance of Cambridge hybrid closed-loop app with this glucose sensor is comparable to other commercially available hybrid closed-loop systems.

Keywords: CamAPS FX; automated insulin delivery; hybrid closed loop; real world evidence.